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Melanoma incidence and, mortality rates in fair-skinned
populations are increasing, and despite a major effort in
clinical research scrutinizing various treatment regimens the
prognosis for these patients still remains poor. The treat-
ment options tested have ranged from monochemotherapy
and polychemotherapeutic approaches as well as immuno-
modulatory therapies using defined cytokines and more
recently cell-based vaccination strategies with dendritic
cells. Although immuno-modulatory approaches are cur-
rently regarded as the most promising, to date no improved
overall survival has been achieved by any of these
measures, especially if examined in multicenter trials
(Eigentler et al, 2003). Melanoma is the most immunogenic
tumor among all neoplasia and therefore the initiation of
a melanoma-specific immune response by the patient’s
immune system may be crucial for a successful tumor
attack. Thus, it represented a ‘‘hypothesis-driven’’ approach
to investigate the potential of immune response modifiers
like imiquimod for the topical treatment of melanoma
(Powell et al, 2004). Imidazoquinoline compounds have
potent antiviral and antitumor properties in animals, have
been clinically approved for the treatment of genital warts
caused by human papillomavirus, and show promise for the
treatment of pre-cancerous cells of the skin (Sauder, 2003).
Extensive studies over the past years have indicated that
imiquimod affects the innate as well as the adaptive
immune system by indirect (e.g., induction of immune
modulatory cytokines) or direct (activation of toll-like
receptors (TLRs) 7 and 8) action on diverse immune cells
including dendritic cells (Hemmi et al, 2002). Based on this
knowledge, the clinical regression of epithelial or melano-
cytic malign lesions following treatment with imiquimod was
thought to mainly involve the activation of the innate and
adaptive cellular immune response of the tumor host
(Hurwitz et al, 2003). In this issue of the JID, Scho¨n et al
demonstrate that more pleiotrophic antitumoral responses
have to be considered when studying imidazoquinolines.
They demonstrate that imiquimod, but not resiquimod (R-
848) is able to act not only as synthetic adjuvant but also as
direct inducer of apoptosis for melanoma cells in vitro and
in vivo. Remarkably, this proapoptotic effect did not require
cells of the adaptive immune system as shown by in vitro
studies with melanoma cell lines. Similar to recent findings
by the same group for keratinocyte-derived skin neoplasias
(Scho¨n et al, 2003), this proapoptotic signal is selectively
activated in melanoma cells, but not in primary human
melanocytes. The study was initially prompted by the
observation that imiquimod directly interferes with cell
viability of melanoma cells in vitro. The authors then
observed that doses of imiquimod in a range likely obtained
in vivo directly induce tumor cell death. Further experiments
confirmed that cell death was exerted by apoptosis rather
than necrosis. Having examined the proapoptotic effect on
melanoma cells in vitro, the authors went on and showed
that imiquimod indeed induces apoptotic cell death in vivo
when applied to cutaneous metastases. Intriguingly, mela-
noma cell lines generated from cutaneous metastases that
did not respond to the topical application of imiquimod were
also resistant to imiquimod in vitro, giving further circum-
stantial evidence for the biological relevance of the pro-
apoptotic response to imiquimod.
How might imiquimod activate the apoptotic program in
melanoma cells? Several pathways leading to the induction
of apoptosis have been described over the last years.
Scho¨n et al started to examine the role of these different cell
death pathways and first showed that imiquimod-induced
apoptosis requires the activation of the ‘‘work horses’’ of
apoptosis necessary for the unique phenotype of apoptotic
cells, namely, the caspase family of proteases (Nicholson,
1999). A widely studied pathway for the induction of
apoptosis is the ‘‘extrinsic’’ cell death pathway, when
apoptosis is triggered from the outside of the cell by death
receptors like TNF-R1, TRAMP, CD95, TRAIL-R1 and -R2,
DR6, and EDA-R (Locksley et al, 2001). These transmem-
brane proteins trigger apoptosis by multimerization upon
ligand binding via a cytoplasmic ‘‘death domain’’ that
recruits the adaptor molecule Fas-associated death domain
(FADD) and subsequently the initiator caspases 8 and/or 10
(Leverkus et al, 2003). Scho¨n et al then demonstrated that
imiquimod initiated the apoptotic program of melanoma
cells independent of the ‘‘extrinsic’’ pathway of apoptosis in
that blocking of individual members of the death receptor
family (CD95, TRAIL-R1, -R2, or TNF-R1) was unable to
interfere with imiquimod-induced cell death. Alternatively,
apoptosis can be triggered via an ‘‘intrinsic’’ cell death
pathway converging at the mitochondria. Many chemo-
therapeutic drugs are known to activate this intrinsic cell
death pathway, eventually leading to the release of proapop-
totic molecules like AIF, Smac, HtrA2, cytochrome c, and
endonuclease G (Debatin et al, 2002). These molecules
either activate caspase 9 in a multimeric complex called the
apoptosome or exert their deleterious function for the cell
in a caspase-independent manner (van Loo et al, 2002). In
contrast to the signals activated by death receptors, the
initiation of the intrinsic death cascade is less well under-
stood and may involve p53-dependent and -independent
modulation of Bcl-2 proteins. The Bcl-2 family of proteinsAbbreviation: TLR, toll-like receptor
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consists of antiapoptotic (e.g., Bcl-2, Bcl-XL, A1, Boo) and
proapoptotic subgroups (e.g., Bax, Bak, or ‘‘BH3-only’’
proteins like Bim, Bid, Bmf, Noxa, and Puma). Since their
discovery, Bcl-2 and its homologues have been associated
with cancer, and are of crucial importance for the regulation
of the intrinsic cell death pathway (Coultas and Strasser,
2003). To ask the question if imiquimod activates the
intrinsic cell death pathway, Scho¨n et al have studied the
role of Bcl-2 and Bax during imiquimod-induced apoptosis.
When they examined the mitochondria-associated levels
of the proapoptotic Bax and the antiapoptotic Bcl-2, they
could show that in imiquimod-susceptible melanoma lines
increased Bax translocation to mitochondria is detected,
whereas imiquimod-resistant lines did not translocate Bax
to mitochondria. Finally, functional studies using a murine
Bcl-2 viral expression construct confirmed that Bcl-2 over-
expression was able to block imiquimod-induced apoptosis,
narrowing down the cellular pathways leading to imiquimod-
induced cell death. It thus appears that selective interference
with components of the proapoptotic cascade upstream of
mitochondria is responsible for imiquimod-induced apopto-
sis of melanoma cells.
Several important questions arise from this study. What
is the direct cellular target of imiquimod? Why does
imiquimod, but not resiquimod activates a proapoptotic
response? Imidazoquinolines activate TLR7 and TLR8, and
proinflammatory signals elicited by these receptors are
mediated via the MyD88-IRAK-TRAF6 pathway, subse-
quently leading to the activation of transcription factors like
Jun N-terminal kinase (JNK), p38, activating protein-1 (AP-
1) and nuclear factor-kB (NF-kB) (Yamamoto et al, 2004). In
addition, MyD88 was shown to interact with FADD and the
stoichiometry of these proteins at the TLR receptor complex
may modify the outcome of receptor triggering (Bannerman
et al, 2002; Ruckdeschel et al, 2002). It is tempting to
speculate that imiquimod exerts its proapoptotic potential
by recruitment of death domain proteins like FADD to TLR7
or TLR8 via MyD88, thereby activating downstream targets
in the apoptotic signalling cascade. Alternatively, TLR
triggering may differentially activate MyD88-independent
apoptic pathways involving TRAM-TRIF-PKR as reported
for TLR4 (Hsu et al, 2004). Intriguingly, the balance between
antiapoptotic (e.g., NF-kB activation) and proapoptotic
(e.g., caspase activation) signals may be modulated in a
cell type or tumor-specific manner, ultimately shifting the
fine-tuned balance between inflammation and cell death.
Therefore, it will be interesting to study the quantitative
responses to different imidazoquinolines in either resistant
or sensitive melanoma cells in more detail. Obviously there
are more possibilities, including a role for different affinities
of these compounds to distinct TLR’s or differences in the
internalization following ligation by TLR agonists as recently
suggested (Heil et al, 2003). In order to test these hypothe-
ses, further studies selectively interfering with receptor-
mediated pro- and antiapoptotic signals are required.
Once the exact mechanism of imiquimod-induced
apoptosis is clarified, it may lead to the identification of
related compounds that preserve the proapoptotic ability
but lack the proinflammatory potential of these TLR ligands.
Moreover it may enable the identification of more success-
ful treatment regimens that utilize knowledge about tumor-
specific properties of apoptosis resistance. Thus more
efficient killers from the same family of compounds may
allow for the initiation of the apoptotic program without a
prominent proinflammatory response, and these agents
might be useful for future tumor therapies in melanoma.
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